| The COVID-19 pandemic: how can risk science help? T Aven, F Bouder Journal of Risk Research 23 (7-8), 849-854, 2020 | 122 | 2020 |
| The tolerability of Risk F Bouder, D Slavin, RE Lofstedt A New Framework for Risk Management. London: Earthscan, 2007 | 120 | 2007 |
| The changing nature of communication and regulation of risk in Europe R Lofstedt, F Bouder, J Wardman, S Chakraborty Journal of Risk Research 14 (4), 409-429, 2011 | 110 | 2011 |
| Transparency in Europe: a quantitative study F Bouder, D Way, R Löfstedt, D Evensen Risk Analysis 35 (7), 1210-1229, 2015 | 75 | 2015 |
| New transparency policies: Risk communication's doom? RE Löfstedt, F Bouder Effective risk communication, 73-90, 2013 | 41 | 2013 |
| Evidence-based uncertainty analysis: What should we now do in Europe? A view point R Lofstedt, F Bouder Journal of Risk Research 24 (5), 521-540, 2021 | 40 | 2021 |
| Regulating impurities in pharmaceutical products: a tolerability of risk approach? F Bouder Expert Review of Clinical Pharmacology 1 (2), 241-250, 2008 | 40 | 2008 |
| The Potsdam radon communication manifesto F Bouder, T Perko, R Lofstedt, O Renn, C Rossmann, D Hevey, M Siegrist, ... Journal of Risk Research 24 (7), 909-912, 2021 | 30 | 2021 |
| Varieties of risk regulation in Europe: coordination, complementarity and occupational safety in capitalist welfare states H Rothstein, D Demeritt, R Paul, AL Beaussier, M Wesseling, M Howard, ... Socio-Economic Review 17 (4), 993-1020, 2019 | 29 | 2019 |
| Pharmaceutical benefit–risk communication tools: a review of the literature D Way, H Blazsin, R Löfstedt, F Bouder Drug safety 40, 15-36, 2017 | 29 | 2017 |
| Medicines transparency at the European Medicines Agency (EMA) in the new information age: the perspectives of patients D Way, F Bouder, R Löfstedt, D Evensen Journal of Risk Research 19 (9), 1185-1215, 2016 | 27 | 2016 |
| Risk communication of vaccines: challenges in the post-trust environment F Bouder Current drug safety 10 (1), 9-15, 2015 | 20 | 2015 |
| When ‘must’means ‘maybe’: varieties of risk regulation and the problem of trade-offs in Europe H Rothstein, AL Beaussier, O Borraz, F Bouder, D Demeritt, M de Haan, ... HowSAFE WP 1, 15, 2015 | 15 | 2015 |
| The future of risk communication and the role of the pharmaceutical industry S Chakraborty, F Bouder Current drug safety 8 (1), 4-10, 2013 | 15 | 2013 |
| Effects of public trust on behavioural intentions in the pharmaceutical sector: data from six European countries D Balog-Way, D Evensen, R Löfstedt, F Bouder Journal of Risk Research 24 (6), 645-672, 2021 | 14 | 2021 |
| Risk-based governance against national obstacles? Comparative dynamics of Europeanization in Dutch, French, and German flooding policies R Paul, F Bouder, M Wesseling Journal of Risk Research 19 (8), 1043-1062, 2016 | 14 | 2016 |
| Transparency and the Food and Drug Administration—A quantitative study R Lofstedt, F Bouder, S Chakraborty Journal of health communication 18 (4), 391-396, 2013 | 14 | 2013 |
| Governance for sustainable development in Canada F Bouder Governance for Sustainable Development: Five OECD Case Studies, Paris: OECD, 2001 | 12 | 2001 |
| Benefit/risk communication by the European Medicines Agency: a study of influential stakeholders' expectations and attitudes F Bouder European Medicines Agency (EMA), 2011 | 11 | 2011 |
| Prioritizing polio B Rath, M Ali, C Elemuwa, W Maurer, F Bouder, E Mworozi, S Diedrich, ... Expert review of vaccines 11 (12), 1389-1392, 2012 | 10 | 2012 |
